2018 Annual Report

Expanding Access
to public health

Impact of the mpp's work: 2010-2018

9

patent holders signed agreements with the MPP

18

products licensed to the MPP

140

active and ongoing product development projects have led to

56

regulatory filings for HIV products

and

14

filings for hepatitis C medicines with stringent regulatory authorities

24

generic manufacturers and product developers sublicensed from the MPP

Generic products
facilitated by the MPP have been distributed in
136 countries,
providing treatment to more than
22 million
patient-years from January 2012 to December 2018

MPP licences
have generated
USD 1.06 billion
in global health savings through the procurement
of more affordable
quality-assured medicines
from MPP generic partners

through
an average price reduction of
73%
relative to
originator price

Download
this chapter

Mission

Our mission is to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries (LMICs) through an innovative approach to voluntary licensing and patent pooling. We work with a range of partners – civil society, international organisations, industry, patient groups and governments – to prioritise and license novel and existing medicines and health technologies for people in these countries.

Vision

Our vision is a world in which people in need in LMICs have rapid access to effective and affordable medical treatments and health technologies.

Strategy 2018-2022

In May, the MPP launched its new strategic direction for 2018–2022, setting targets for improving access to medicines for people living with HIV, hepatitis C and tuberculosis in LMICs. Based on the findings of a feasibility study, the plan also recommends the expansion of the MPP model to patented medicines with high medical value, starting with small molecules on the World Health Organization Model List of Essential Medicines (WHO EML).

The MPP will measure it success based on achieving
the following five targets by 2022

More than 20 million people living with HIV in LMICs are treated with MPP-licensed antiretrovirals.

The MPP has licensed patented medicines that are on the WHO EML or are likely to be added in the future.

Curative, pan-genotypic hepatitis C treatments are available for ≤ USD 50 per person from quality-assured suppliers in licensed countries.

The MedsPaL database incorporates up-to-date reliable intellectual property status information on all patented essential medicines for all LMICs.

Shortened all-oral regimen with the potential for use in drug-resistant and drug-susceptible tuberculosis is licensed to the MPP.

HIV

Of the 36.9 million people living with HIV globally in 2017,
21.7 million had access to antiretroviral treatment,
an increase of 2.3 million since 2016 and up from 8 million in 2010.1

Of the 36.9 million people living with HIV globally in 2017,
21.7 million had access to antiretroviral treatment,
an increase of 2.3 million since 2016 and up from 8 million in 2010.1

[2017]

36.9M

PEOPLE LIVING
WITH HIV,INCLUDING
1.8M CHILDREN

41%

adults

48%

children

MISS OUT ON HIV TREATMENT, OF WHOM THE VAST MAJORITY LIVE IN LOW- AND MIDDLE-INCOME COUNTRIES

1 UNITAID, 2019 Factsheet

See how MPP's work is increasing access to HIV medicines in low- and middle-income countries - world map visualisation.

Choose product:

dolutegravir (DTG) 50mg

tenofovir disoproxil/lamivudine/ dolutegravir (TDF/3TC/DTG – TLD)

tenofovir alafenamide/ emtricitabine/dolutegravir (TAF/FTC/DTG)

atazanavir/ritonavir (ATV/r)

lopinavir/ritonavir (LPV/r)

lopinavir/ritonavir (LPV/r) paediatric

Choose status:

COVERED TERRITORY
94
COUNTRIES

FILED IN
22
COUNTRIES

APPROVED IN
19
COUNTRIES

SOLD IN
56
COUNTRIES

High-income countries

Low- and middle-income countries

COVERED TERRITORY
94
COUNTRIES

FILED IN
23
COUNTRIES

APPROVED IN
19
COUNTRIES

SOLD IN
27
COUNTRIES

High-income countries

Low- and middle-income countries

COVERED TERRITORY
87
COUNTRIES

FILED IN
8
COUNTRIES*

APPROVED IN
4
COUNTRIES

High-income countries

Low- and middle-income countries

*For confidential purposes, the list of filed countries will
be disclosed when more than one approval from stringent
regulatory authorities is granted

COVERED TERRITORY
54
COUNTRIES

FILED IN
12
COUNTRIES

APPROVED IN
35
COUNTRIES

SOLD IN
83
COUNTRIES

High-income countries

Low- and middle-income countries

COVERED TERRITORY
54
COUNTRIES

FILED IN
4
COUNTRIES

APPROVED IN
33
COUNTRIES

SOLD IN
70
COUNTRIES

High-income countries

Low- and middle-income countries

COVERED TERRITORY
102
COUNTRIES

FILED IN
10
COUNTRIES*

APPROVED IN
9
COUNTRIES

High-income countries

Low- and middle-income countries

*For confidential purposes, the list of filed countries will
be disclosed when more than one approval from stringent
regulatory authorities is granted

Hepatitis C

Direct-acting antiviral medicines can cure more than 95% of patients
but access to diagnosis and treatment is low especially in low- and
middle-income countries,
where the vast majority of people with the virus live.2

Direct-acting antiviral medicines can cure more than 95% of patients
but access to diagnosis and treatment is low especially in low- and
middle-income countries,
where the vast majority of people with the virus live.
of 2.3 million since 2016 and up from 8 million in 2010.2

71M

PEOPLE HAVE
CHRONIC HEPATITIS C INFECTION

2015
20%
LIVING WITH
HEPATITIS C VIRUS
(HCV) INFECTION
KNEW THEIR
DIAGNOSIS

2015-2016
13%
STARTED ON
TREATMENT

THERE IS STILL
A MAJOR GAP
TO ACHIEVE
THE 80% TREATMENT TARGET BY 2030.

2 World Health Organization,Key Facts

See how MPP's work is increasing access to Hepatitis C medicines in low- and middle-income countries - world map visualisation.

Choose product:

daclatasvir 30mg and 60mg

daclatasvir + sofosbuvir (DAC + SOF)

Choose status:

COVERED TERRITORY
112
COUNTRIES

FILED IN
29
COUNTRIES

APPROVED IN
25
COUNTRIES

SOLD IN
13
COUNTRIES

High-income countries

Low- and middle-income countries

COVERED TERRITORY
112
COUNTRIES

FILED IN
16
COUNTRIES*

APPROVED IN
5
COUNTRIES

SOLD IN
2
COUNTRIES

High-income countries

Low- and middle-income countries

*For confidential purposes, the list of filed countries will
be disclosed when more than one approval from stringent
regulatory authorities is granted

Tuberculosis

TB is one of the top ten killers globally and the leading killer of HIV-positive people.3

TB is one of the top ten killers globally and the leading killer of HIV-positive people.3

10
Million

FELL ILL WITH
TB IN 2017

2017
87%
OF NEW TB CASES
OCCURRED IN THE
30 HIGH TB BURDEN COUNTRIES*

1.6
Million

DIED
including
230,000 children

Ending the TB epidemic
by 2030 is amongst the health
targets of the Sustainable
Development Goals.

To meet this target, faster-acting,
better therapies to treat TB are urgent,
particularly for MDR-TB

3 World Health Organization, Fact Sheet
* Which are all low- and middle-income countries

Download
this chapter

Technical Expertise

In 2018, the MPP continued to support efforts to accelerate access to high-quality low-cost medical treatments and health technologies through the development of new tools and publication of reports.

MPP-Unitaid report released on long-acting technologies

Interactive antiretroviral projections tool launched

Annual Prioritisation Report

The Medicines Patents and Licences Database

Download
this chapter

Financial statements

for the year ended 31 December 2018 and Report of the Statutory Auditor